Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
Healthcare
Page 11- Jun 02, 2026 · 18:00 · ONCO · Routine +01
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
- Jun 02, 2026 · 17:00 · SEGN · Routine −02
Seegnal Raises $1.3M at a Discount to Fund Burn Rate as Filing Delays and Going Concern Risks Mount
Seegnal Inc. Announces Non-Brokered Private Placement
- Jun 02, 2026 · 16:05 · BCT · Routine −03
BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment
BriaCell Therapeutics Announces Closing of Offering
- Jun 02, 2026 · 09:03 · PHA · Material −04
Insolvent staffing firm signals deeper lender standoff as it delays critical filings and seeks management-only trading ban.
Premier Health of America Announces Anticipated Delay in Filing Interim Financial Statements and Application for Management Cease Trade Order
- Jun 02, 2026 · 08:48 · OTC · Routine +05
Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones
Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones
- Jun 02, 2026 · 08:00 · AIDR · Routine +06
AI Virtual Care Platform Accelerates U.S. Visits and Secures Cash Runway, But Margin Compression and Going Concern Doubts Loom
Rocket Doctor AI Announces Strong Q1 Momentum Driven by U.S. Expansion, New Payer Contracts and Platform Growth
- Jun 02, 2026 · 07:01 · BPC · Routine +07
The Precision Peptide Company Inc.
The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States
- Jun 02, 2026 · 06:31 · WELL · Material +08
WELL Health Improves Guidance Based on WELL Canada Achieving $100 Million in Annualized Adjusted EBITDA Run-Rate Ahead of Schedule
WELL Health Improves Guidance Based on WELL Canada Achieving $100 Million in Annualized Adjusted EBITDA Run-Rate Ahead of Schedule
- Jun 02, 2026 · 00:03 · VST · Routine +09
Victory Square Q1 Revenue Hits Guidance Floor as Hydreight Scales and Insu Advances to Phase II
Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update
- Jun 01, 2026 · 22:00 · LOBE · Neutral10
Lobe Sciences Settles $1.37M Debt with Equity, Advances L-130 and S-100 Clinical Programs
Lobe Sciences Announces Proposed Shares for Debt Transaction
- Jun 01, 2026 · 21:32 · NURS · Routine +11
Hydreight's Q1 EBITDA Margin Expansion Validates Operating Leverage, But Valuation Premium Demands Flawless Execution
Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA Superscript 2 and $32.0 Million in Working Capital
- Jun 01, 2026 · 20:59 · CTX · Routine +12
Crescita Therapeutics Inc.
Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv
- Jun 01, 2026 · 19:30 · 4565 · Routine +13
Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
- Jun 01, 2026 · 19:30 · QNTM · Material −14
A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.
Quantum BioPharma Provides Corporate Update